Stay updated on Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.

Latest updates to the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added; the lapse-in-government-funding notice and Revision: v3.4.1 were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH Clinical Center operations was added. The page revision tag was updated to v3.4.1, replacing the previous v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedUI and labeling updates include showing a glossary option, updating the 'Last Update Submitted that Met QC Criteria' label and adding 'No FEAR Act Data' and 'Revision: v3.4.0'. The prior labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page's revision history shows the addition of Revision: v3.3.4 and removal of Revision: v3.3.3, a minor backend update with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedA new Locations section is added, listing Pennsylvania and NSW 2310 sites. The old separate location blocks and the HHS Vulnerability Disclosure link were removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.3%

- Check85 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2; no substantive changes to trial content or eligibility criteria were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Palbociclib With Standard Treatment in Residual Breast Cancer Clinical Trial page.